跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IBSRELA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
IBSRELA
Authorized
STANDARD
IBSRELA
knight therapeutics inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
22d0bc944bfca2ff
Company
knight therapeutics inc.
Type
Standard
Approval Details
Approval Id
22d0bc944bfca2ff
Drug Approval Canada Name
IBSRELA
Product Name
IBSRELA
Status
Marketed
Status Date
2020-11-23
Original Market Date
2020-11-23
Din
02498049
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
40:18.19
Atc Original
A06AX08 TENAPANOR
Atc Name
a 06 ax 08
Aig Number
0162174001
Company Name
knight therapeutics inc.
Company Address
1055, 3400 De Maisonneuve Blvd W, Montreal, Quebec, Canada, H3Z 3B8
Active Ingredients
TENAPANOR (TENAPANOR HYDROCHLORIDE)
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
22d0bc944bfca2ff
Type
Standard
Back to Health Canada Approvals